Episealer® technology to be presented at international scientific congress
Episurf Medical (Nasdaq: EPIS B) today announces that the Episealer® technology will be presented at the 7th ICRS (International Cartilage Regeneration & Joint Preservation Society) Summit in Catania, Italy, on September 25-27, 2024. The Episealer® technology will be presented at two sessions as part of the scientific program.
Dr. Gary Levengood of Sports Medicine South, part of the Northside Health System, GA, USA, has been invited to present his experience using the Episealer® Patellofemoral System, introduced on the US market in 2023. This is the first time usage of the Episealer® Patellofemoral System will be presented at a congress of this kind. Dr. Francesca de Caro, Pavia City Orthopedics Health Institute, Pavia, Italy, will present the Episealer Knee® technology, including an update from an ongoing investigator-initiated study with up to 10 years’ follow-up of Episealer® Knee patients.
”We are honored that ICRS, a society previously more focused on biological treatment alternatives, has dedicated two sessions within the scientific program to our technology. Our Episealer® Knee implant has become a standardized part of treatment algorithms at several clinics, and we have experienced high interest in our Episealer® Patellofemoral system since the market introduction in the US last year, including from surgeons such as Dr. Levengood who have previously been amongst the highest volume users of competitive systems. The fact that our technology is highlighted at this international congress with many leading surgeons confirms the genuine interest in our concept, and we look forward to the event”, says Pål Ryfors, CEO Episurf Medical.
The Episealer® Patellofemoral system is a fully individualized implant system for treating osteoarthritis in the patellofemoral compartment of the knee joint. The system is cleared by FDA, United States Food and Drug Administration. The Episealer® Knee system is a fully individualized implant system for the treatment of chondral and osteochondral lesions in the knee joint. The system is CE marked and available in approximately 20 countries globally.
